TOKYO, May 29 (Pulse News Wire) – Shionogi & CO.,LTD. (4507.T) announced that its subsidiary, Shionogi Limited, received approval from the National Medical Products Administration (NMPA) in China for Nardejemin Tosylate, a treatment for opioid-induced constipation (OIC).
The approval was based on positive results from Phase III clinical trials conducted in China and abroad. Nardejemin, developed by Shionogi, is a peripherally acting μ-opioid receptor antagonist that improves OIC without affecting the analgesic effects of opioids used for pain management. It is currently sold under various brand names—Swimplorik®, Symproic®, and Rizmoic®—in Japan, the United States, and Europe. In China, Chong Kun Digital Pharmaceutical Group Co., Ltd.
Will handle sales and distribution of the drug. Chong Kun Digital, a key subsidiary of China Biologic Products Holdings, Inc., operates across multiple locations in Shanghai, Nanjing, and Lianyungang, employing more than 7,000 academic and sales staff members. The company's extensive network supports the promotion and distribution of Nardejemin in China. The impact of this approval on Shionogi’s consolidated performance for the fiscal year ending March 2027 is expected to be minor.
🟢 Confidence: High AI-translated content.